Moderna's Vaccine Portfolio Primed For Boost From Its COVID-19 Work
At its "Vaccines Day" with investors, Moderna execs tout the company's messenger RNA platform and say its portfolio of vaccine candidates has the potential to reach annual peak sales of up to $12bn.
You may also be interested in...
US cost watchdog ICER has released its cost models for remdesivir, and says it wants to stimulate debate on how it and other COVID-19 therapies should be priced. Plus news from Amgen and ILC Therapeutics.
Pfizer said it is dosing patients now with an mRNA-based vaccine and expects human data in May/June, with a goal to have a vaccine available for emergency use possibly by October.
Public Company Edition: ORIC’s initial public offering is the third by a drug developer in April and the 12th in 2020. Also, Pluristem garnered €50m from the European Investment Bank.